The FDA’s database for application ANDA077777 lists alprazolam extended‑release tablets marketed by Sandoz Inc.
All four product numbers (001, 002, 003, 004) are marked as discontinued. These oral tablets are available in strengths of 0.5 mg, 1 mg, 2 mg, and 3 mg.
The submission history includes an original ANDA (submission 1) approved on 30 June 2006, and several labeling supplement submissions (numbers 4, 6, and 7) approved on 22 November 2011 and 30 June 2023.
No reference drug status or reference standard is indicated for these products.
Regulatorische Updates30. Aug. 2026•1 Min. Lesezeit
FDA Discontinues Alprazolam Extended‑Release Tablets (ANDA077777)
FDA records show Sandoz's alprazolam extended‑release tablets (product numbers 001‑004) are discontinued, with multiple labeling supplement approvals.
Zusammengestellt vom PharmaCountry-Team · Quelle: FDA.gov
Bewertungen
(0)
(0)
(0)
(0)
(0)
Weitere Artikel
Alle Einblicke anzeigenStudien & Berichte
Global Finished Dosage Manufacturing Landscape 2026
5. Okt. 2026
Regulatorische UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28. Sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28. Sept. 2026
Bewertung hinterlassen